Jefferies & Company has raised the price target on HealthSpring (NYSE:
HS) from $46 to $48 and maintains its Buy rating.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
